Veracyte Inc
NASDAQ:VCYT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
18.86
39.53
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VCYT stock under the Base Case scenario is 17.529 USD. Compared to the current market price of 38.285 USD, Veracyte Inc is Overvalued by 54%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Veracyte Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VCYT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Veracyte Inc
Balance Sheet Decomposition
Veracyte Inc
Current Assets | 356.9m |
Cash & Short-Term Investments | 274.1m |
Receivables | 48.8m |
Other Current Assets | 34m |
Non-Current Assets | 918.2m |
PP&E | 38.2m |
Intangibles | 871m |
Other Non-Current Assets | 9m |
Current Liabilities | 70.3m |
Accounts Payable | 9.7m |
Accrued Liabilities | 51.2m |
Other Current Liabilities | 9.5m |
Non-Current Liabilities | 28.7m |
Long-Term Debt | 100k |
Other Non-Current Liabilities | 28.6m |
Earnings Waterfall
Veracyte Inc
Revenue
|
425.3m
USD
|
Cost of Revenue
|
-134.2m
USD
|
Gross Profit
|
291.1m
USD
|
Operating Expenses
|
-282m
USD
|
Operating Income
|
9.1m
USD
|
Other Expenses
|
-18.4m
USD
|
Net Income
|
-9.3m
USD
|
Free Cash Flow Analysis
Veracyte Inc
USD | |
Free Cash Flow | USD |
VCYT Profitability Score
Profitability Due Diligence
Veracyte Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Veracyte Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
VCYT Solvency Score
Solvency Due Diligence
Veracyte Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Veracyte Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VCYT Price Targets Summary
Veracyte Inc
According to Wall Street analysts, the average 1-year price target for VCYT is 37.967 USD with a low forecast of 26.26 USD and a high forecast of 45.15 USD.
Dividends
Current shareholder yield for VCYT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.
Contact
IPO
Employees
Officers
The intrinsic value of one VCYT stock under the Base Case scenario is 17.529 USD.
Compared to the current market price of 38.285 USD, Veracyte Inc is Overvalued by 54%.